Display options
Cite
Zaid AN, Cortesi R, Qaddomi A, et al. Formulation and bioequivalence of two valsartan tablets after a single oral administration. Sci Pharm. 2010;79(1):123-35doi: 10.3797/scipharm.1009-01.
Zaid, A. N., Cortesi, R., Qaddomi, A., & Khammash, S. (2011). Formulation and bioequivalence of two valsartan tablets after a single oral administration. Scientia pharmaceutica, 79(1), 123-35. https://doi.org/10.3797/scipharm.1009-01
Zaid, Abdel Naser, et al. "Formulation and bioequivalence of two valsartan tablets after a single oral administration." Scientia pharmaceutica vol. 79,1 (2011): 123-35. doi: https://doi.org/10.3797/scipharm.1009-01
Zaid AN, Cortesi R, Qaddomi A, Khammash S. Formulation and bioequivalence of two valsartan tablets after a single oral administration. Sci Pharm. 2011 Jan-Mar;79(1):123-35. doi: 10.3797/scipharm.1009-01. Epub 2010 Nov 20. PMID: 21617777; PMCID: PMC3097505.
Copy Download .nbib Format: NLM
Share it on

Sci Pharm. 2011 Jan-Mar;79(1):123-35. doi: 10.3797/scipharm.1009-01. Epub 2010 Nov 20.

Formulation and bioequivalence of two valsartan tablets after a single oral administration.

Scientia pharmaceutica

Abdel Naser Zaid, Rita Cortesi, Aiman Qaddomi, Saed Khammash

Affiliations

  1. College of Pharmacy, An-Najah National University, P.O. Box: 7, Nablus, Palestine. [email protected]

PMID: 21617777 PMCID: PMC3097505 DOI: 10.3797/scipharm.1009-01

Abstract

The aim of this study is to assess the quality of Valzan(®) tablet (160 mg, valsartan immediate release test formulation) by comparing its pharmacokinetic parameters with Diovan(®) tablet (160 mg, valsartan reference formulation). Valzan(®) tablets were prepared according to a dry granulation method (roll compaction). To assess the bioequivalence of Valzan(®) tablets a randomized, two-way, crossover, bioequivalence study was performed in 24 healthy male volunteers. The selected volunteers were divided into two groups of 12 subjects. One group was treated with the reference formulation (Diovan(®)) and the other one with the generic Valzan(®), with a cross-over after the drug washout period of 14 days. Blood samples were collected at fixed time intervals and valsartan concentrations were determined by a validated HPLC assay method. The pharmacokinetic parameters AUC(0-48), AUC(0-∞), C(max), T(max), K(e) and T(1/2) were determined for both the tablets and were compared statistically to evaluate the bioequivalence between the two brands of valsartan, using the statistical model recommended by the FDA. The analysis of variance (ANOVA) did not show any significant difference between the two formulations and 90% confidence intervals (CI) fell within the acceptable range for bioequivalence. Based on this statistical evaluation it was concluded that the test tablets (Valzan(®)) is well formulated, since it exhibits pharmacokinetic profile comparable to the reference brand Diovan(®).

Keywords: Bioequivalence; Diovan®; Formulation; HPLC; Immediate Release; Valsartan; Valzan®

References

  1. Clin Ther. 1996 Sep-Oct;18(5):797-810 - PubMed
  2. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 17;832(1):169-72 - PubMed
  3. Arch Pharm Res. 2008 Aug;31(8):1055-9 - PubMed
  4. Clin Pharmacol Ther. 1996 Sep;60(3):341-6 - PubMed
  5. J Clin Invest. 2007 Nov;117(11):3393-402 - PubMed
  6. Pharm Res. 2007 Oct;24(10):1962-73 - PubMed
  7. Xenobiotica. 1997 Jan;27(1):59-71 - PubMed
  8. Eur J Clin Pharmacol. 1997;52(6):441-9 - PubMed
  9. Eur J Clin Pharmacol. 1997;52(2):115-20 - PubMed
  10. J Hum Hypertens. 1997 Aug;11(8):483-9 - PubMed
  11. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 25;766(2):345-9 - PubMed
  12. Int J Clin Pharmacol Ther. 2002 Jan;40(1):35-40 - PubMed
  13. Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):249-55 - PubMed
  14. Clin Pharmacol Ther. 1997 Sep;62(3):272-8 - PubMed
  15. Indian J Pharm Sci. 2008 May-Jun;70(3):372-4 - PubMed
  16. J Hypertens. 1996 Sep;14(9):1147-51 - PubMed
  17. Arzneimittelforschung. 2010;60(2):76-80 - PubMed

Publication Types